Delving into the Latest Updates on Pegaspargase biosimilar(Gennova Biopharmaceuticals Ltd.) with Synapse

Overview

Basic Info

Drug Type

Biosimilar, Enzyme

Synonyms-

Target

ASN

Mechanism

ASN inhibitors(Asparagine inhibitors)

Therapeutic Areas

NeoplasmsImmune System DiseasesHemic and Lymphatic Diseases

Active Indication

Acute Lymphoblastic Leukemia

Inactive Indication-

Originator Organization

Gennova Biopharmaceuticals Ltd.

Active Organization

Gennova Biopharmaceuticals Ltd.

Inactive Organization-

Drug Highest PhaseApproved

First Approval Date-

Regulation-

Login to view timeline

Gene Sequence

Sequence Code 92226

The sequence is quoted from: *****

RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. It is not yet known which combination chemotherapy regimen is more effective in treating young patients with acute lymphoblastic leukemia.
PURPOSE: This partially randomized phase III trial is studying how well combination chemotherapy works in treating young patients with relapsed or refractory acute lymphoblastic leukemia.

Start Date01 Oct 2002

Sponsor / Collaborator-

100 Clinical Results associated with Pegaspargase biosimilar(Gennova Biopharmaceuticals Ltd.)

Login to view more data

100 Translational Medicine associated with Pegaspargase biosimilar(Gennova Biopharmaceuticals Ltd.)

Login to view more data

100 Patents (Medical) associated with Pegaspargase biosimilar(Gennova Biopharmaceuticals Ltd.)

Login to view more data

100 Deals associated with Pegaspargase biosimilar(Gennova Biopharmaceuticals Ltd.)

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	L01XX24	-

R&D Status

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Acute Lymphoblastic Leukemia	IN	Gennova Biopharmaceuticals Ltd.	-

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT01483690 (CTgov)	Phase 1/2	Recurrent Adult Acute Lymphoblastic Leukemia \| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma \| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma	23	Vorinostat+Pegaspargase+Decitabine+dexamethasone+Methotrexate+Vincristine+mitoxantrone (Initial Dose Level)	hmquzcipro(idcrdrrfdn) = tdkxoeiycn nklssbujwc (ospiyknipk, bkblktmegs - ggktnravgb) View more	-	27 Oct 2020
				Vorinostat+Pegaspargase+Decitabine+dexamethasone+Methotrexate+Vincristine+mitoxantrone (Modified Dose Level)	hmquzcipro(idcrdrrfdn) = wgcnvwfacm nklssbujwc (ospiyknipk, gwmkkqoale - lwvylqdbii) View more